BackAbCellera Biologics Overview

AbCellera Biologics Current Cash

AbCellera Biologics's current cash is $77M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$77.06M
↓ 51.61% YoYΔ $-82.20M vs prior year quarter

Peer average

Loading

AbCellera Biologics Current Cash History

Loading

AbCellera Biologics vs. peers: Current Cash Comparison

Loading

AbCellera Biologics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AbCellera Biologics (ABCL) FAQ

The latest current cash for ABCL is $77M as of March 2026. That compares with $160M in the prior-year period — down 51.6% year over year. Investors often review this figure alongside AbCellera Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABCL's current cash moved from $160M to $77M — a 51.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AbCellera Biologics's operating scale or balance-sheet position.

A current cash figure of $77M for ABCL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ABCL's current cash ($77M), review year-over-year change from $160M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.